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Small Animals
Mycotic rhinitis-rhinosinusitis, most commonly caused by Aspergillus fumigatus,1 is a common 
cause of chronic nasal discharge in dogs.2 Chronic mu-
copurulent nasal discharge, nasal pain, and ulceration 
and depigmentation of the nasal planum are typical 
clinical signs on evaluation; epistaxis might also be 
present.3 Diagnosis is made on the basis of endoscop-
ic visualization of fungal plaques in the nasal cavity, 
frontal sinuses, or both as well as results of a combi-
nation of further diagnostic tests such as CT, biopsy, 
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OBJECTIVE
To evaluate outcomes for dogs with mycotic rhinitis-rhinosinusitis (MRR) 
treated by meticulous debridement and topical application of 1% clotrima-
zole cream and investigate potential prognostic factors that could help pre-
dict whether 1 or multiple treatments would be needed for clinical resolu-
tion of the condition.
DESIGN
Retrospective case series.
ANIMALS
64 dogs.
PROCEDURES
Medical records were reviewed to identify dogs treated for MRR by meticu-
lous debridement and topical application of 1% clotrimazole cream. Signal-
ment, clinical signs, previous treatments, CT findings, presence of unilateral 
or bilateral disease, predisposing factors, number and type of treatments, 
and complications were recorded. Outcome information was obtained 
from records or by telephone interview with owners. Association of se-
lected factors with the number of treatments needed for clinical resolution 
was evaluated.
RESULTS
Clotrimazole was instilled via the trephination site (n = 42) or under endo-
scopic guidance (22). Thirteen dogs underwent a 5-minute flush with 1% 
clotrimazole solution prior to cream application, and 34 received adjunctive 
oral itraconazole treatment. The MRR was deemed resolved in 58 dogs, 
and clinical signs persisted in 1 dog. Five dogs died (2 of causes unrelated to 
MRR) ≤ 1 month after treatment. The first treatment was successful in 42 
of 62 (68%) dogs; overall success rate was 58 of 62 (94%). No prognostic 
factors for the number of treatments needed to provide clinical resolution 
were identified. Seven dogs with reinfection were successfully retreated.
CONCLUSIONS AND CLINICAL RELEVANCE
Topical treatment by meticulous debridement and 1% clotrimazole cream 
application had results similar to or better than those described in other 
studies of dogs with MRR. Trephination or adjunctive itraconazole treat-
ment did not influence the number of treatments needed for a successful 
outcome. ( J Am Vet Med Assoc 2017;250:309–315)
fungal culture, cytologic examination, and serologic 
testing.4 Orally and topically administered antifungal 
agents have been used to treat MRR with variable suc-
cess. Clinical improvement was observed in 20 of 47 
and 6 of 10 of dogs that were treated with oral anti-
fungal agents.5,6 Topical antifungal agents (enilcon-
azole, clotrimazole, bifonazole) are available in vari-
ous formulations (eg, creams or solutions with various 
concentrations of the active compounds). These are 
administered directly into the nasal cavity, frontal si-
nuses, or both through means such as surgically im-
planted indwelling catheters in the frontal sinuses,7 
temporary trephination of the frontal sinuses,8–12 tem-
porary frontal sinus catheters placed under endoscop-
ic guidance,13–15 or temporary catheters placed blindly 
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into the nasal cavities.8,11–14,16 Topical administration 
of antifungal agents is usually preceded by removal of 
fungal plaques and necrotic tissue. Although several 
treatment regimens have been described, an optimal 
treatment is unknown, and the disease course is often 
frustrating for clinicians and owners because multiple 
treatments can be necessary.3
The purpose of the study reported here was to 
retrospectively evaluate the outcomes for dogs that 
underwent treatment of MRR by meticulous debride-
ment and instillation of clotrimazole cream with en-
doscopic guidance or through a trephination site. A 
second aim was to identify potential prognostic fac-
tors that could help to predict whether 1 or multiple 
treatments would be necessary for clinical resolution 
of the condition.
Materials and Methods
Case selection
Electronic medical records of a university veteri-
nary teaching hospital (Small Animal Clinic, Justus- 
Liebig-University Giessen) and a veterinary referral 
hospital (Tierklinik Hofheim) were searched to iden-
tify dogs with a diagnosis of MRR that underwent 
treatment between September 28, 2007, and Septem-
ber 2, 2014. Each dog was included in the study only 
once. Dogs treated by meticulous debridement fol-
lowed by application of 1% clotrimazole cream into 
the nasal cavities and frontal sinuses via trephination 
or via antegrade rhinoscopy were eligible for study 
inclusion. Dogs that received additional topical treat-
ment by flushing with a 1% clotrimazole solution for 
5 minutes, oral antifungal treatment, or both were 
included in the study. Dogs treated by soaking the af-
fected region with clotrimazole solution for an hour 
were excluded.
Diagnosis of MRR was made on the basis of en-
doscopic visualization of fungal plaques in nasal 
cavities, frontal sinuses, or both, with associated na-
sal turbinate destruction.13,17 Additional diagnostic 
procedures included CT, histologic examination of 
nasal biopsy samples, fungal culture, and cytologic 
examination of imprints of nasal biopsy samples, as 
determined by the attending clinician. The CT im-
ages were evaluated at the time of examination by 
a board-certified radiologist or national specialist in 
diagnostic imaging. In these reports, destruction of 
the turbinates with presence of abnormal soft tissue 
in the nasal passages, thickening of the mucosa, and 
hyperostosis or lysis of surrounding bone were con-
sidered suggestive of fungal rhinitis.18 Frontal sinus 
involvement was suspected if mucosal thickening, 
presence of abnormal soft tissue within a frontal si-
nus, hyperostosis or lysis affecting frontal bones, or 
a combination of these findings was identified on CT 
images.18
Medical records review
Information obtained from medical records in-
cluded signalment (age, breed, and sex), duration and 
types of clinical signs (eg, presence of unilateral or 
bilateral nasal discharge or epistaxis), previous treat-
ments (corticosteroid or antimicrobial administration 
[including previous antifungal treatment]), CT find-
ings (eg, involvement of frontal sinus or disruption 
of the cribriform plate), presence of unilateral or 
bilateral nasal disease (determined by evaluation of 
CT images, rhinoscopy findings, or both), and pres-
ence of any predisposing factors (eg, foreign body, 
previous head trauma, dental disease, or systemic 
immunosuppression). The number and type of topi-
cal clotrimazole treatments, type and dosage of anti-
fungal medications administered orally after topical 
treatment (if applicable), complications attributed to 
treatment, and patient outcome (eg, number of treat-
ments necessary until clinical resolution, persistence 
of mild serous nasal discharge after treatment, dura-
tion of follow-up, and whether reinfection was diag-
nosed) were also recorded.
Procedures
Computed tomography (when used) and rhinos-
copy were performed in patients under general anes-
thesia. For analgesia, an opioid agent (eg, buprenor-
phine, methadone, or fentanyl), regional (infraorbital 
nerve) blockade with lidocaine, or both were provid-
ed. Dogs were placed in sternal recumbency. For CT, 
a helical CT scannera (technical settings of 120 kV, 
350 mA, and slice thickness of 2 mm) was used to ob-
tain images of the affected region. The images were 
viewed with soft tissue (window level, 70 HUs; win-
dow width, 400 HUs) and bone (window level, 900 
HUs; window width, 2,200 HUs) settings. Retrograde 
rhinoscopy was performed with a bronchoscope (5.2 
mm X 85 cm)b or a rigid endoscope (4 mm X 18 cm; 
120° view)c and followed by anterograde rhinoscopy 
with a multipurpose rigid endoscope (2.7 mm X 18 
cm, 30° or 0° view)d,e or bronchoscope (3.0 mm X 
100 cm or 5.2 mm X 85 cm).b,f Rhinoscopy, trephina-
tion, and treatment at the referral hospital were per-
formed by one of the authors (CS). At the university 
teaching hospital, several clinicians with various ex-
perience levels performed the rhinoscopy and treat-
ment procedures; however, this was supervised by 
one of the authors (RN).
After diagnostic rhinoscopy, most dogs treated at 
the university teaching hospital underwent trephina-
tion irrespective of evidence of frontal sinus involve-
ment on CT. Rolled cotton gauze was placed in the 
pharynx, and trephination was performed midway 
between the zygomatic process of the frontal bone 
and 1 cm lateral to the midline with a 6-mm bone 
drill.
For dogs seen at the referral hospital, the deci-
sion to trephine the frontal sinuses was made on the 
basis of evidence of frontal sinus involvement on CT 
and endoscopic accessibility of the sinuses; in dogs 
with severe turbinate destruction, debridement of 
the frontal sinus was possible rhinoscopically with 
an antegrade approach. If the frontal sinus could not 
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be accessed via rhinoscopy in dogs that had frontal 
sinus involvement identified by CT, trephination was 
performed.
Any samples for cytologic or histologic exami-
nation or fungal culture were obtained prior to 
debridement and application of topical antifungal 
medication. The first part of the treatment consist-
ed of meticulous debridement. If trephination was 
performed, fungal plaques were loosened with a 
curette and removed from the affected frontal sinus 
mostly by use of suction. The remaining material was 
flushed out through the nasal opening with copious 
amounts of balanced electrolyte solution (up to 5 L). 
If no trephination was performed, fungal plaques and 
necrotic material in the sinus were loosened with for-
ceps under endoscopic guidance and then flushed 
out. Once there was no evidence of fungal material 
left in the frontal sinus, flushing and suction were 
continued in the nasal cavity. This procedure of flush-
ing and suctioning, lasting up to 2 hours, was per-
formed until all visible fungal material and necrotic 
tissue were removed.
Subsequently, 1% clotrimazole creamg was in-
stilled via a 9F feeding tubeh into each affected fron-
tal sinus until cream could be seen leaking from the 
nares. Depending on the dog’s size and head confor-
mation, 30 to 100 mL of the cream was used for each 
sinus and nasal cavity. In some dogs, administration 
of the cream was preceded by a short flush with 1% 
clotrimazole solutioni (50 mL in dogs weighing ≤ 20 
kg [44 lb] and 100 mL in dogs weighing > 20 kg). 
The use of clotrimazole cream and clotrimazole so-
lution for treatment of MRR in dogs was extralabel, 
because no product was licensed for this indication 
in Germany.
Some dogs received a course of oral antifungal 
agent administration beginning at the time of hospi-
talization for debridement and topical treatment. The 
decision of whether or not to treat systemically in ad-
dition to the topical treatment was made at the at-
tending clinician’s discretion.
Recheck rhinoscopy was performed 3 to 8 weeks 
after debridement and topical treatment to confirm 
resolution of MRR or to repeat treatment in dogs with 
persistent clinical signs and visible fungal plaques. 
Resolution of MRR was defined as absence of visible 
fungal plaques with no or negligible amounts of ne-
crotic turbinate material present. The latter, if present, 
was nevertheless removed endoscopically. Some dogs 
that had follow-up rhinoscopy received an additional 
treatment with clotrimazole cream in the absence of 
visible fungal plaques if deemed appropriate by the at-
tending clinician, on the basis of the knowledge that 
microscopic residual disease cannot be ruled out by 
endoscopic visualization. Because the additional treat-
ment was not administered on the basis of the pres-
ence of visible fungal plaques, it was not included in 
calculations of the number of treatments necessary 
until clinical resolution.11 In dogs that did not have fol-
low-up rhinoscopy performed, MRR was considered to 
have resolved if no clinical signs or only mild serous 
nasal discharge was present for > 6 months9 after the 
treatment on the basis of information collected from 
the owners by telephone. Reinfection was defined as 
recurrence of mucopurulent or hemorrhagic nasal dis-
charge (or both) and the presence of fungal plaques on 
rhinoscopy ≥ 12 months after the initial infection was 
deemed resolved.
Statistical analysis
Distribution of the data was assessed by the 
Kolmogorov-Smirnov test; the data were found to be 
nonnormally distributed. The associations of various 
factors (patient age; duration of clinical signs; pres-
ence of unilateral or bilateral disease, epistaxis, or 
frontal sinus involvement; whether oral antifungal 
treatment was administered; whether trephination 
was performed; and the treating institution) with the 
number of treatments necessary until clinical resolu-
tion (1 vs > 1) were tested by the Mann-Whitney U 
test (for numeric variables) and Fisher exact test (for 
categorical variables). Values of P < 0.05 were accept-
ed as significant. Commercially available statistical 
softwarej was used for all analyses.
Results
Eighty dogs (24 at the university teaching hospi-
tal and 56 at the referral hospital) were treated for 
MRR during the study period. Sixteen dogs (all treat-
ed at the referral hospital) were excluded because 
they were treated by methods other than those under 
evaluation. The median age of the 64 dogs included 
in the study was 5.2 years (range, 0.4 to 14.75 years). 
Forty-four were male and 20 were female. Forty-five 
were purebred dogs, with Golden Retriever (n = 8), 
German Shepherd Dog (4), and Labrador Retriever 
(3) being the most commonly represented breeds. 
Eighteen dogs were of mixed breeding, and the breed 
was not recorded for 1. Forty dogs had unilateral and 
20 had bilateral nasal discharge, and for 4 dogs this 
information was not recorded. Thirty-eight dogs had 
epistaxis. Median duration of clinical signs was 2.5 
months (range, 0.5 to 24 months).
In addition to rhinoscopic examination, proce-
dures performed to confirm or support the diagnosis 
or further assess the extent of disease included CT (n 
= 62), histologic examination of nasal biopsy samples 
(35), fungal culture (30), and cytologic examination 
of imprints from nasal biopsy samples (19). The CT 
examination revealed evidence of unilateral MRR in 
46 dogs, involvement of the frontal sinus in 41, and 
disruption of the cribriform plate in 8. Rhinoscopy 
was suggestive of unilateral MRR in 47 dogs. For 6 
dogs, there was discordance between rhinoscopic 
and CT findings regarding the presence of unilateral 
or bilateral disease. The disease in these dogs was 
considered bilateral on the basis of evidence of bilat-
eral involvement with one of the diagnostic modali-
ties. For 3 dogs, fungal plaques were found unilater-
ally on rhinoscopy but typical turbinate destruction 
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was present bilaterally on CT, and the opposite find-
ings were recorded for the remaining 3 dogs.
Possible predisposing factors were identified for 
17 dogs. These included head trauma, dental disease, 
foreign body, and systemic immunosuppression or 
systemic immunosuppressive treatment. Head trau-
ma was reported by the owners of 4 dogs, and sup-
portive evidence was present on CT examination (eg, 
evidence of previous fractures) in all 4. Where dental 
disease was present and considered a possible pre-
disposing factor (n = 4), it was treated as appropriate 
(eg, by tooth extraction). A foreign body (plant mate-
rial) was identified on initial endoscopic evaluation 
in 4 dogs and removed in all 4. Immunosuppressive 
treatment was discontinued prior to examination at 
the university teaching hospital or referral hospital 
for 3 dogs, and for 1 dog, this was not possible owing 
to relapse of the immune-mediated disease (polyar-
thritis). One dog was found to be neutropenic, but 
the underlying condition was unknown.
Nine dogs had received oral antifungal treatments 
(itraconazole [n = 7] or ketoconazole [2]) prior to exam-
ination and treatment at the authors’ institutions; these 
medications had been discontinued prior to evaluation. 
Seven dogs had previously received local treatment 
(soak with an antifungal agent [n = 5] or rhinotomy [2]).
Most (42/64 [66%]) dogs underwent trephination. 
Seven of these dogs had the procedure performed de-
spite the lack of evidence of frontal sinus involvement 
on CT. Fungal plaques were not found in the sinuses in 
any of these dogs, but were present in the nasal cavi-
ties in all 7. Twenty-two dogs had no trephination per-
formed because of either rhinoscopic accessibility of 
the frontal sinuses (n = 8) or lack of evidence of sinus 
involvement on CT (14). A short flushing procedure 
with 1% clotrimazole solution was performed for 13 
dogs after trephination and prior to instillation of the 
1% clotrimazole cream. Thirty-four dogs (5 treated at 
the university teaching hospital and 29 treated at the 
referral hospital) received a 3-month course of treat-
ment with itraconazole (5 mg/kg [2.3 mg/lb], PO, q 24 
h) beginning at the time of the first topical treatment.
Recheck rhinoscopy was performed for 50 dogs 
3 to 8 weeks after the initial clotrimazole treatment. 
Resolution of MRR was confirmed in 32 of 50 dogs 
at that time (including 24 that received a follow-up 
clotrimazole cream treatment in the absence of vis-
ible fungal plaques). The remaining 18 dogs under-
went repeated treatment at this visit because of per-
sistent clinical signs and residual fungal plaques.
Overall, MRR was deemed resolved in 58 of 64 
(91%) dogs; 9 of these 58 (16%) underwent flushing 
with clotrimazole solution prior to the cream instilla-
tion, and 49 (84%) did not. Resolution of the disease 
was confirmed with rhinoscopy for 38 dogs; 32 of these 
needed 1 treatment, 5 needed 2 treatments, and 1 need-
ed 3 treatments. Resolution of the disease was reported 
on the basis of telephone interview with the owners for 
the remaining 20 dogs. Mild serous nasal discharge per-
sisted after resolution of MRR in 20 dogs; 16 of these 20 
had clinical resolution confirmed by follow-up rhinos-
copy. Mucopurulent nasal discharge persisted in 1 dog, 
and 5 dogs died ≤ 1 month after the treatment, before 
resolution could be evaluated. Two dogs were reported 
to have died from conditions unrelated to the infection 
(splenic tumor and pancytopenia of unknown origin), 
and 3 died of conditions possibly associated with the 
disease or its treatment. Excluding the 2 dogs that died 
of unrelated causes, treatment was successful in 58 of 
62 (94%) dogs overall. Forty-two of 58 (72%) dogs that 
were successfully treated required only 1 treatment for 
clinical resolution of the disease. Among successfully 
treated dogs, infection was deemed resolved after only 
1 treatment for 5 of 9 dogs that received the combina-
tion of a brief clotrimazole solution flush and clotrima-
zole cream, compared with 37 of 49 (76%) of dogs with 
this outcome following treatment with the cream only. 
Use of the clotrimazole flush prior to the application 
of the cream was not significantly associated with the 
number of treatments required for clinical resolution 
of the infection (Table 1). Furthermore, there were 
no significant differences between dogs that needed 1 
versus ≥ 2 treatments in regard to age, duration of clini-
cal signs, presence of unilateral versus bilateral disease, 
presence of epistaxis, additional systemic itraconazole 
treatment, frontal sinus involvement on CT, treatment 
approach through trephination, or institution where 
the treatment was performed.
The overall treatment complication rate was 12 of 
64 (19%) when deaths possibly attributable to MRR or its 
treatment were included; the rate for non–life-threatening 
complications was 9 of 64 (14%). Most of the treatment 
complications were mild and temporary. Mild swelling 
was noted after trephination in 7 dogs, and 1 dog had 
an abscess at the trephination site necessitating surgical 
debridement. One dog developed aspiration pneumo-
nia and recovered with antimicrobial treatment. Of the 
3 dogs with deaths considered attributable to the fungal 
disease or treatment complications, 1 dog that initially 
improved after the sole treatment died suddenly after 
recurrence of nasal discharge within a few weeks. One 
dog with previous head trauma and seizures continued 
having seizures after the treatment and was euthanized. 
This dog had evidence of disruption of the cribriform 
plate and pneumocephalus identified by MRI at the time 
of initial examination. The third dog had severe epistaxis 
on the day after treatment that necessitated blood trans-
fusion and was eventually euthanized.
One dog had persistent nasal discharge after 1 treat-
ment, but further treatment was declined by the owner. 
This dog was subsequently euthanized because of per-
sistent clinical signs and was categorized as having treat-
ment failure.
Seven dogs had reinfection diagnosed a median of 
18 months (range, 12 to 30 months) after treatment (or 
last treatment for dogs that needed > 1 treatment). All 7 
dogs had received a 3-month course of itraconazole at the 
time of their initial treatment for MRR. The reinfection 
occurred on the same side of the nasal cavity in dogs with 
unilateral disease at the time of the first evaluation (n = 
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6) and bilaterally in 1 dog with bilateral involvement on 
initial examination. In all 7 dogs, there was frontal sinus 
involvement in both episodes of infection. Five of these 
dogs had received 1 clotrimazole treatment before clini-
cal resolution of the initial infection, and 2 had required 
≥ 2 treatments before clinical resolution was achieved. 
Clinical resolution of the disease had been confirmed by 
rhinoscopy in 5 of these dogs. All 7 dogs with reinfection 
were successfully treated again.
Discussion
The present study identified a high success rate for 
the treatment of MRR by meticulous debridement and ap-
plication of 1% clotrimazole cream. Most (42/62 [68%]) 
dogs had clinical resolution after only 1 treatment, and 
the overall success rate (including dogs that underwent 
2 or 3 treatments) was 58 of 62 (94%) after exclusion of 
2 dogs that died of causes unrelated to MRR or its treat-
ment. This compares favorably to most previous reports 
of topical antifungal treatment in dogs for this condition, 
where success rates after the first treatment of 39 of 85 
(46%) to 12 of 14 (86%) and overall success rates from 59 
of 85 (69%) to 24 of 26 (92%) were found.8–13,15 Howev-
er, direct comparison of treatment success among these 
studies is difficult because of the variation in methods of 
outcome evaluation (eg, endoscopic examination, clini-
cal reexamination, or telephone reports).
None of the pretreatment factors evaluated (pa-
tient age, duration of clinical signs, unilateral vs bi-
lateral disease, presence of epistaxis, or frontal sinus 
involvement) or factors associated with treatment (ac-
cess by trephination vs rhinoscopy, use of a 5-minute 
flush with 1% clotrimazole solution before application 
of the cream, oral itraconazole administration, or fa-
cility where the procedures were performed) signifi-
cantly influenced the number of treatments needed 
for clinical resolution of MRR among dogs that had a 
successful outcome. Although clotrimazole solution 
might cause some chemical irritation of the mucosa 
and, in this way, possibly contribute to debridement, 
we did not identify any association between its use and 
the number of treatments required for clinical resolu-
tion. However, this result could have been attributable 
to the low number of dogs that received a 5-minute 
clotrimazole flush in the present study (9 for which 
treatment was successful). The main difference among 
the treatment protocols for individual dogs in this 
study was in the technique for accessing the frontal 
sinus. Trephination also did not influence the number 
of treatments necessary for resolution of the disease 
among dogs with successful outcomes. Importantly, 
no fungal plaques were found in frontal sinuses of 7 
dogs that had trephination despite the lack of evidence 
of sinus involvement on CT. These findings suggest 
that trephination may not be needed in dogs without 
evidence of frontal sinus involvement on CT. Although 
trephination might enable better access to the fron-
tal sinus, we do not consider this technique to be an 
essential part of the treatment as long as meticulous 
debridement and application of clotrimazole cream 
can be performed via endoscopic methods. In agree-
   No. of treatments  
Variable 1 (n = 42) 2–3 (n = 16) P value
Age (y) 5.5 (0.4–14.75)  4.6 (0.5–12.5) 0.281
Duration of clinical signs (mo) 2.5 (0.5–24.0) 2 (0.5–18.0) 0.746
Epistaxis 23 12                       0.359
Distribution                         0.052
  Unilateral disease 33 8 
  Bilateral disease 9 8 
Frontal sinus involvement 28 10 0.642
Systemic treatment with itraconazole 23                       9                      1.0
Trephination 24 12 0.243
Brief clotrimazole flush 5 4 0.243
Treating institution   0.373
  University teaching hospital 13 7 
  Referral hospital 29 9 
Data are absolute values or median (range). Sixty-four dogs that underwent treatment by 
application of clotrimazole cream with or without a brief (5-minute) flush with 1% clotrima-
zole solution immediately prior to instillation of the cream were included in the retrospec-
tive study; 6 dogs were excluded from this analysis because the disease was not considered 
resolved (owing to persistent nasal discharge following treatment [n = 1] or death for MRR-
related [3] or unrelated causes [2] ≤ 1 month after the initial treatment). Disease resolution 
was confirmed by follow-up rhinoscopy of 38 dogs and was concluded  on the basis of infor-
mation obtained in telephone interviews with the owners of 20 dogs.
Table 1—Results of analysis for association of variables of interest with the num-
ber of topical treatments (1 vs > 1 application of 1% clotrimazole cream through 
a trephination site or by rhinoscopic methods) needed until clinical resolution of 
MRR in 58 dogs treated at 2 hospitals.
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ment with others,11,13,15 we regard debridement as an 
important part of the treatment. However, some inves-
tigators did not specify debridement as a part of their 
treatment protocols9,10 and achieved treatment success 
rates comparable to those of our study. Only 1 prelimi-
nary report specifically addressed the importance of 
completeness of the debridement.19 In that study,19 a 
significantly higher percentage (22/28 [79%]) of dogs 
was cured with only 1 treatment when debridement 
was complete, compared with dogs that had incom-
plete debridement (8/20 [40%]). It could be argued 
that debridement prolongs anesthetic time; however, 
this potential disadvantage could be outweighed if 
its use might obviate further treatment. Additional re-
search in this area is warranted.
Clotrimazole cream was chosen as the topical anti-
fungal agent for dogs in the present study for a variety 
of reasons. The cream was previously shown to have 
good distribution in the nasal cavities and frontal si-
nuses of canine cadavers.20,21 Prolonged retention of 
the cream was shown in a cadaver study,20 whereas 
poor retention of the irrigation solution was found in 
client-owned dogs with MRR.22 Prolonged retention 
would enable prolonged contact time of the antifungal 
agent with any residual fungal particles. It is currently 
unknown whether the contact time achieved by the 
application of clotrimazole cream yields results supe-
rior to those that can be achieved with an alternative 
method in which the affected region is soaked for 1 
hour with the antifungal agent in solution. However, 
with the latter treatment, the anesthetic time would 
be approximately 1 hour longer than that needed for 
instillation of the cream under endoscopic guidance or 
after trephination. Considering the substantial amount 
of time that might have already been spent on debride-
ment prior to the application of the antifungal agent, 
choosing a faster method might be preferable, espe-
cially in older or debilitated dogs.
Younger dogs were identified as having a greater 
chance of treatment success in a previous study.12 In 
that same study,12 there was no significant associa-
tion between frontal sinus involvement or duration 
of clinical signs and treatment success. In the present 
study, none of these factors were significantly associ-
ated with the number of treatments (1 vs 2 or 3) need-
ed for clinical resolution in the 58 dogs that had a 
successful outcome. Adjunctive treatment with orally 
administered antifungal agents was associated with 
treatment failure in the aforementioned study,12 but 
our study found no association between adjunctive 
treatment with oral itraconazole administration and 
the number of treatments until clinical resolution. 
Oral itraconazole treatment did not prevent reinfec-
tion in the present study; all 7 dogs that had reinfec-
tion received oral itraconazole at the time of their 
initial clotrimazole treatment. The limited effect of 
systemic antifungal treatment likely reflects the his-
tologic findings associated with MRR, indicating that 
fungal elements are found on the mucosal surface 
rather than invading the mucosa.23
Mild swelling and abscess formation at the treph-
ination site occurred in the present study and in pre-
vious studies8,10; however, in general, the treatment 
was well tolerated. One dog in our study developed 
severe epistaxis the day after treatment necessitating 
a blood transfusion, and was eventually euthanized. 
It cannot be ruled out that the epistaxis was associat-
ed with the treatment, but it was considered unlikely 
given that this did not occur during or immediately 
after the treatment. Severe epistaxis was reported13 
in 2 dogs treated by infusion and soaking of affected 
nasal passages with enilconazole; however, this oc-
curred immediately after removal of the nasal cath-
eters used for the treatment.
Persistence of mild serous nasal discharge, oc-
casional sneezing, or both was reported in approxi-
mately half (9/20 and 14/27) of successfully treated 
dogs in 2 studies,9,14 and mild serous nasal discharge 
was identified in 20 of 58 (34%) dogs in the present 
study. Irreversible turbinate destruction predisposing 
the dogs to develop bacterial rhinitis and persistent 
lymphoplasmacytic rhinitis after successful treat-
ment of MRR have been discussed as possible reasons 
for these mild persistent signs.14
Reinfection was identified in 7 successfully treated 
dogs in the present study. The reinfection rate (7/58 
[12%]) was similar to results of previous reports in 
which 3 of 15 (20%) and 3 of 27 (11%) dogs, respec-
tively, had recurrence of MRR.11,14 Although the same 
side of the nasal cavity was affected at the time of re-
currence and persistence of fungal disease could not 
be completely ruled out, it was considered less likely 
given the time interval between the last treatment and 
recurrence of clinical signs. It has been suggested that 
turbinate destruction could make the nasal cavity more 
susceptible to reinfection.11 All 7 dogs that had reinfec-
tion in this study, as well as 3 of 3 dogs described in an-
other report,11 had frontal sinus involvement. However, 
it is unclear whether this finding has clinical relevance.
A major limitation of this study was its retrospec-
tive character, which caused some data to be missing. 
Considering the study design and inclusion of dogs 
from 2 hospitals, the treatments might not have been 
uniform in all dogs. Performing trephination in some 
but not all dogs with frontal sinus involvement could 
have been a source of bias. Furthermore, treatments 
performed at the university teaching hospital might 
not have been completely standardized because sev-
eral clinicians with various degrees of experience 
performed the treatments, although the procedure 
was supervised by one of the authors (RN). As there 
was no standardized way of describing rhinoscopic 
findings and the treatment procedure itself, it was 
not always possible to evaluate the extent and sever-
ity of MRR, which might have influenced treatment 
outcome. Another limitation was that the resolution 
of MRR was not confirmed rhinoscopically in 20 of 
58 (34%) dogs that were deemed to have successful 
treatment. However, removing dogs without endo-
scopic reassessment had no influence on the results 
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of the statistical analysis (data not shown). Further-
more, even in dogs that had follow-up rhinoscopy 
performed, no culture or histologic evaluation of 
nasal biopsy specimens was performed to confirm 
resolution of MRR. This might have been particularly 
important in dogs with small amounts of necrotic tur-
binate material present on follow-up endoscopy. In 
these dogs, necrotic material was visually differenti-
ated from fungal plaques on the basis of the prem-
ise that necrotic parts of the turbinates can be eas-
ily separated from the mucosa by touching with the 
endoscope or forceps. However, culture or histologic 
examination of what was considered necrotic mate-
rial from these patients might have enabled more reli-
able differentiation than visual inspection. Although 
unlikely, if fungal particles were mistaken for necrot-
ic material, the application of clotrimazole cream at 
the follow-up endoscopy would have been necessary 
to achieve resolution of the disease and would have 
to be calculated in the number of treatments needed 
for this outcome. In this case, the 7 dogs that had 
negligible amounts of necrotic material on follow-up 
rhinoscopy would have been considered successfully 
treated after 2 treatments, rather than 1 treatment.
Overall, topical treatment by meticulous debride-
ment and application of 1% clotrimazole cream either 
via a trephination site or endoscopically into the af-
fected frontal sinuses and nasal cavities had a success-
ful result in most dogs after the first treatment. The 
overall success rate (58/62 [94%]) was considered ex-
cellent, and the treatment was well tolerated in most 
dogs.
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Footnotes
a. CT scanner Brilliance 16, Philips Healthcare, Best, The 
Netherlands.
b. Broncho-Fiberscope, catalogue No. 60001 VL1, Karl Storz, 
Tuttlingen, Germany.
c. HOPKINS II Retrograde Telescope 120°, Karl Storz, Tuttlin-
gen, Germany.
d. HOPKINS II Straight Forward Telescope 0°, Karl Storz, Tut-
tlingen, Germany.
e. HOPKINS II Forward-Oblique Telescope 30°, Karl Storz, Tut-
tlingen, Germany.
f. Broncho-Fiberscope, Karl Storz, Tuttlingen, Germany.
g. Canesten Crème, Bayer, Leverkusen, Germany.
h. Feeding tube, B. Braun, Melsungen, Germany.
i. Fungizid Pumpspray, Ratiopharm, Ulm, Germany.
j. SPSS, version 22.0, IBM, Armonk, NY.
References
1. Talbot JJ, Johnson L, Martin P, et al. What causes canine sino-
nasal aspergillosis? A molecular approach to species identifi-
cation. Vet J 2014;200:17–21.
2. Meler E, Dunn M, Lecuyer M. A retrospective study of ca-
nine persistent nasal disease: 80 cases (1998–2003). Can Vet 
J 2008;49:71–76.
3. Sharman MJ, Mansfield CS. Sinonasal aspergillosis in dogs: a 
review. J Small Anim Pract 2012;53:434–444.
4. Imholt K, Koch C, Freese F, et al. Sinunasale Aspergillose des 
Hundes–Symptome, Diagnose und Therapie. Kleintierpraxis 
2014;59:565–584.
5. Harvey CE. Nasal aspergillosis and penicillosis in dogs: re-
sults of treatment with thiabendazole. J Am Vet Med Assoc 
1984;184:48–50.
6. Sharp NJH, Harvey CE, O’Brien JA. Treatment of canine na-
sal aspergillosis/penicilliosis with fluconazole. J Small Anim 
Pract 1991;32:513–516.
7. Sharp NJH, Sullivan M, Harvey CE, et al. Treatment of ca-
nine nasal aspergillosis with enilconazole. J Vet Intern Med 
1993;7:40–43.
8. Mathews KG, Davidson A, Koblik P, et al. Comparison of topi-
cal administration of clotrimazole through surgically placed 
versus nonsurgically placed catheters for treatment of nasal 
aspergillosis in dogs: 60 cases (1990–1996). J Am Vet Med 
Assoc 1998;213:501–506.
9. Friend EJ, Williams JM, White RAS. Invasive treatment of 
canine nasal aspergillosis with topical clotrimazole. Vet Rec 
2002;151:298–299.
10. Sissener TR, Bacon NJ, Friend E, et al. Combined clotrima-
zole irrigation and depot therapy for canine nasal aspergil-
losis. J Small Anim Pract 2006;47:312–315.
11. Pomrantz JS, Johnson LR. Repeated rhinoscopic and sero-
logic assessment of the effectiveness of intranasally adminis-
tered clotrimazole for the treatment of nasal aspergillosis in 
dogs. J Am Vet Med Assoc 2010;236:757–762.
12. Sharman M, Paul A, Davies D, et al. Multicentre assessment 
of mycotic rhinosinusitis in dogs: a retrospective study of ini-
tial treatment success (1998 to 2008). J Small Anim Pract 
2010;51:423–427.
13. Zonderland JL, Störk CK, Saunders JH, et al. Intranasal infu-
sion of enilconazole for treatment of sinonasal aspergillosis 
in dogs. J Am Vet Med Assoc 2002;221:1421–1425.
14. Schuller S, Clercx C. Long-term outcomes in dogs with si-
nonasal aspergillosis treated with intranasal infusions of 
enilconazole. J Am Anim Hosp Assoc 2007;43:33–38.
15. Billen F, Guieu L, Bernaerts F, et al. Efficacy of intrasinusal 
administration of bifonazole cream alone or in combination 
with enilconazole irrigation in canine sino-nasal aspergillo-
sis: 17 cases. Can Vet J 2010;51:164–168.
16. Bray JP, White RAS, Lascelles BDX. Treatment of canine na-
sal aspergillosis with a new non-invasive technique. Failure 
with enilconazole. J Small Anim Pract 1998;39:223–226.
17. Peeters D, Clercx C. Update on canine sinonasal aspergillo-
sis. Vet Clin North Am Small Anim Pract 2007;37:901–916.
18. Saunders JH, Zonderland J, Clercx C, et al. Computed tomo-
graphic findings in 35 dogs with nasal aspergillosis. Vet Ra-
diol Ultrasound 2002;43:5–9.
19. Girod M, Goosens D, Volpe R, et al. Comparison of two non-
invasive 2% enilconazole infusion protocols for treatment of 
canine sinonasal aspergillosis and importance of debridement 
for treatment efficacy. In: Research Communications of the 
25th ECVIM-CA Congress. J Vet Intern Med 2016;30:348–468.
20. Hayes GM, Demetriou JL. Distribution and persistence of 
topical clotrimazole after sinus infusion in normal canine 
cadavers. J Small Anim Pract 2012;53:95–100.
21. Burrow R, Baker M, White L, et al. Trephination of the frontal si-
nuses and instillation of clotrimazole cream: a computed tomo-
graphic study in canine cadavers. Vet Surg 2013;42:322–328.
22. Sharman M, Lenard Z, Hosgood G, et al. Clotrimazole and 
enilconazole distribution within the frontal sinuses and na-
sal cavity of nine dogs with sinonasal aspergillosis. J Small 
Anim Pract 2012;53:161–167.
23. Peeters D, Day MJ, Clercx C. An immunohistochemical study of 
canine nasal aspergillosis. J Comp Pathol 2005;132:283–288.
